Ann: First Human Dose in Phase 1 Clinical Trial of AMP945, page-2

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company” is pleased to announce the dosing of the first subjects in its Phase 1 clinical trial of AMP945, the Company’s experimental Focal Adhesion Kinase inhibitor, which is being developed for difficult-to-treat cancers and fibrotic diseases.

“Dosing the first human subject with AMP945 is a transformative milestone for Amplia and one that has been the key focus for the company”, said Chief Executive Officer, Dr John Lambert. “We expect that this trial will provide the foundation upon which we can build parallel clinical programs in cancer and fibrosis and we are delighted that we have taken this significant step.”


Awesome ...

The start of a new era for ATX

.